Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05956834 · ClinicalTrials.gov registry record

A Multi-Modal Remote Monitoring Platform for Frontotemporal Lobar Degeneration (FTLD) Syndromes

A clinical trial of Frontotemporal Dementia and Progressive Supranuclear Palsy, sponsored by Massachusetts General Hospital.

Active
Registry status
60
Enrollment target
2
Study locations

NCT05956834: Active study of Frontotemporal Dementia and Progressive Supranuclear Palsy, sponsored by Massachusetts General Hospital.

NCT05956834 is a study of Frontotemporal Dementia and Progressive Supranuclear Palsy that is active but no longer recruiting, run by Massachusetts General Hospital. The registered enrollment target is 60 participants, below the 1,195-participant average among 22 other Frontotemporal Dementia trials with a reported enrollment target (95% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05956834, a study of Frontotemporal Dementia and Progressive Supranuclear Palsy, is active but no longer recruiting, sponsored by Massachusetts General Hospital.

ACTIVE NOT RECRUITING
Registry status
60 participants
Enrollment target
2
Study locations

Study Summary

The primary objective of this study is to enroll an observational cohort of approximately 60 patients with PSP over the course of 24 months using a multicenter study design and to follow each of them for 12 months. The secondary objective of this study is to develop a robust solution for multi-modal remote monitoring of motor symptoms and function in PSP that can be applied to other Frontotemporal lobar degeneration (FTLD) syndromes.

Primary Outcome

Feasibility will be defined by the number of participants who complete the 12 month study and who wear their PAMSys pendant sensors at least 16 hours/day for at least 75% of the designated sensor days (7 days per month).

Interventions

  • DEVICE PAMSys
  • DEVICE LEGSys

Study Locations (2)

Maryland

  • Johns Hopkins School of Medicine - Baltimore

Massachusetts

  • Massachusetts General Hospital - Boston

Trial Details

FieldValue
Enrollment Target 60 participants
Start Date 2023-07-28
Est. Completion 2027-12-30
Massachusetts General Hospital

2,032 total trials

What the registry record for NCT05956834 still lists

NCT05956834 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 60 participants, a relatively small participant target, below the 1,195-participant average among 22 other Frontotemporal Dementia trials with a reported enrollment target (95% lower).

The record links to 7 conditions, with Frontotemporal Dementia appearing as the primary indexed condition, and to 2 interventions - of which PAMSys is the first listed.

NCT05956834 reports a single indexed study location in Maryland, Massachusetts.

Frequently Asked Questions

What is clinical trial NCT05956834 about?

NCT05956834 is a clinical study titled "A Multi-Modal Remote Monitoring Platform for Frontotemporal Lobar Degeneration (FTLD) Syndromes". The primary objective of this study is to enroll an observational cohort of approximately 60 patients with PSP over the course of 24 months using a multicenter study design and to follow each of them for 12 months. The secondary objective of this study is to develop a robust solution for multi-moda...

What is the current status of trial NCT05956834?

This trial is currently active not recruiting. The enrollment target is 60 participants. The study started on 2023-07-28. Estimated completion is 2027-12-30.

What conditions does trial NCT05956834 study?

This clinical trial studies the following conditions: Frontotemporal Dementia, Progressive Supranuclear Palsy, CBD, Corticobasal Degeneration, Frontotemporal Lobar Degeneration.

What interventions are being tested in trial NCT05956834?

The interventions under investigation include: PAMSys (DEVICE), LEGSys (DEVICE).

Who is sponsoring clinical trial NCT05956834?

This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05956834 being conducted?

This trial has 2 study locations across Maryland, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Frontotemporal Dementia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05956834's enrollment target sits among peer trials

60 16th of 22 higher than 7 of 22 other Frontotemporal Dementia trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Frontotemporal Dementia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00576069 · 60 participants

    Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma

  • NCT01297400 · 60 participants · Phase 2

    Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns

  • NCT01734122 · 60 participants

    Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor

  • NCT01804634 · 60 participants · Phase 2

    Reduced Intensity Haploidentical BMT for High Risk Solid Tumors

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05956834, the US trial registry maintained by the National Library of Medicine. NCT05956834 (small enrollment · single site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.